Suchergebnisse - "Andrea Forschner"

PubPharm (25)

1

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

in: Journal for ImmunoTherapy of Cancer | 2023

von Dirk Schadendorf | Carola Berking | Jessica C Hassel | +37

2

Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study

in: Cancers | 2023

von Manuel Kolb | Andrea Forschner | Christoph Artzner | +4

3

459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG

in: Journal for ImmunoTherapy of Cancer | 2023

von Dirk Schadendorf | Carola Berking | Lisa Zimmer | +37

4

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

in: Journal for ImmunoTherapy of Cancer | 2023

von Dirk Schadendorf | Lucie Heinzerling | Jessica C Hassel | +44

5

Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma

in: Frontiers in Oncology | 2023

von Charlotte Nübel | Teresa Amaral | Ulrike Leiter | +2

6

Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG

in: Journal for ImmunoTherapy of Cancer | 2022

von Dirk Schadendorf | Lucie Heinzerling | Lisa Zimmer | +35

7

eHealth Literacy in German Skin Cancer Patients

in: International Journal of Environmental Research and Public Health | 2022

von Henner Stege | Sara Schneider | Andrea Forschner | +11

8

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma

in: Cancers | 2022

von Marcus Wölffer | Florian Battke | Martin Schulze | +4

9

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

in: Journal for ImmunoTherapy of Cancer | 2021

von Carola Berking | Thomas K Eigentler | Andrea Forschner | +36

10

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

in: Cancers | 2021

von Lina María Serna-Higuita | Teresa Amaral | Andrea Forschner | +7